Molecular mechanism of miR-204 regulates proliferation, apoptosis and autophagy of cervical cancer cells by targeting ATF2
Source abstract
Abstract
Objective To investigate the regulatory mechanism of miR-204 on proliferation, apoptosis and autophagy of cervical cancer cells.Methods The expression of miR-204 in cervical cancer tissues and cell lines was detected by real-time PCR. Cell viability and apoptosis were detected by MTT and flow cytometry, respectively. Protein expression of Bcl-2, Bax, Caspase-3 and LC3I/II in C33A cells after transfection was detected by Western blot assay. The interaction between miR-204 and ATF2 was verified by Targetscan online prediction, dual-luciferase assay and Western blot.Results The expression of miR-204 was significantly down-regulated in cervical cancer tissues and cell lines (p < .05). Cell viability was suppressed while apoptosis was enhanced in C33A cells transfected with miR-204. In addition, overexpression of miR-204 reduced protein expression of Bcl-2 and LC3I/II and elevated protein expression of Bax and Caspase-3 in C33A cells (p < .05). The results of Targetscan online prediction, dual-luciferase assay and Western blot indicted that miR-204 could regulate the expression of ATF2. Cell viability was increased (p < .05) and the expression of ATF2 and LC3I/II was down-regulated (p < .05) in C33A cells after silencing of ATF2. Ectopic expression of ATF2 could restore miR-204 mediated inhibition on proliferation of C33A cells.Conclusions miR-204 could inhibit proliferation and autophagy and induce apoptosis of cervical cancer cells by targeting ATF2, representing promising target for cervical cancer treatment.
Source: openalex_inverted_index · Quality: baseline
Research context
OpenAlex topics: MicroRNA in disease regulation · Circular RNAs in diseases · Cancer-related molecular mechanisms research
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pathology, The Fourth Affiliated Hospital of Harbin Medical University
Department of Pathology, The Second Affiliated Hospital of Harbin Medical University
Department of Obstetrics and Gynecology, The Fourth Affiliated Hospital of Harbin Medical University
Funding
Heilongjiang Youth Science Foundation
References (23)
Show source-provided references
1. 10.1002/cncr.3066710.1002/cncr.30667 ↗
2. 10.21147/j.issn.1000-9604.2017.06.0110.21147/j.issn.1000-9604.2017.06.01 ↗
3. 10.1016/j.clinthera.2016.02.00710.1016/j.clinthera.2016.02.007 ↗
4. 10.1186/s12967-016-0893-x10.1186/s12967-016-0893-x ↗
5. 10.1038/nrd.2016.24610.1038/nrd.2016.246 ↗
6. Wang X, Qiu W, Zhang G, et al. MicroRNA-204 targets JAK2 in breast cancer and induces cell apoptosis through the STAT3/BCl-2/survivin pathway. Int J Clin Exp Pathol. 2015;8:5017–5025.
7. 10.1007/s12032-014-0331-y10.1007/s12032-014-0331-y ↗
8. 10.1002/cncr.3063010.1002/cncr.30630 ↗
9. 10.3390/ijerph1311114810.3390/ijerph13111148 ↗
10. 10.1080/16549716.2017.133734110.1080/16549716.2017.1337341 ↗
11. Vincerževskienė I, Jasilionis D, Austys D, et al. Education predicts cervical cancer survival: a Lithuanian cohort study. Eur J Public Health. 2017;27:421–424.
12. 10.1172/JCI8544610.1172/JCI85446 ↗
13. Wardak S. Human papillomavirus (HPV) and cervical cancer. Med Dosw Mikrobiol. 2016;68:73–84.
14. Yang DY, Bracken K. Update on the new 9-valent vaccine for human papillomavirus prevention. Can Fam Physician. 2016;62:399–402.
15. 10.4103/2229-3485.17943110.4103/2229-3485.179431 ↗
16. 10.18632/oncotarget.893710.18632/oncotarget.8937 ↗
17. Liu Z, Sun J, Liu B, et al. miRNA-222 promotes liver cancer cell proliferation, migration and invasion and inhibits apoptosis by targeting BBC3. Int J Mol Med. 2018;42:141–148.
18. 10.3233/CBM-15049210.3233/CBM-150492 ↗
19. 10.1007/s13277-016-4848-x10.1007/s13277-016-4848-x ↗
20. Shu L, Zhang Z, Cai Y. MicroRNA-204 inhibits cell migration and invasion in human cervical cancer by regulating transcription factor 12. Oncol Lett. 2018;15:161–166.
21. 10.4161/cc.638810.4161/cc.6388 ↗
22. 10.1186/s13046-016-0383-210.1186/s13046-016-0383-2 ↗
23. 10.18632/oncotarget.1173210.18632/oncotarget.11732 ↗